Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2024 08:30 ET | Source: Alvotech

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

REYKJAVIK, Iceland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...
October 30, 2024 08:30 ET | Source: Alvotech

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first nine months of...
October 30, 2024 08:30 ET | Source: Alvotech

Alvotech mun birta uppgjör fyrstu níu mánaða ársins miðvikudaginn 13. nóvember nk. og streyma uppgjörsfundi fimmtudaginn 14. nóvember nk. kl. 13:00 að íslenskum tíma

Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrir fyrstu níu mánuði ársins 2024 eftir lokun markaða í Bandaríkjunum, miðvikudaginn 13. nóvember nk. Þá mun Alvotech halda...
October 25, 2024 08:00 ET | Source: Alvotech

Alvotech fundar með fjárfestum og heldur kynningu á heilbrigðisráðstefnu Jefferies í London 19.-20. nóvember 2024

Alvotech (NASDAQ: ALVO) fundar með erlendum fjárfestum á heilbrigðisráðstefnu fjárfestingabankans Jefferies, í London dagana 19.- 20. nóvember n.k. Stjórnendur Alvotech munu einnig flytja kynningu á...
October 25, 2024 08:00 ET | Source: Alvotech

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...
October 25, 2024 08:00 ET | Source: Alvotech

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

REYKJAVIK, Iceland, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
October 22, 2024 07:00 ET | Source: Alvotech

Alvotech veitt aukið markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn), líftæknilyfjahliðstæðu við Stelara, til meðferðar sjúkdóma í meltingarvegi

Aukið markaðsleyfi er veitt fyrir Selarsdi í Bandaríkjunum til meðferðar við Crohns- sjúkdómnum og sáraristilbólgu, sem eru þrálátir bólgusjúkdómar í meltingarvegiMatvæla- og lyfjaeftirlit...
October 22, 2024 07:00 ET | Source: Alvotech

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitisThe FDA previously approved...
October 22, 2024 07:00 ET | Source: Alvotech

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved...
October 10, 2024 05:01 ET | Source: Alvotech

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency...